Convalescent Plasma Restores Viral Clearance After Anti-Spike Monoclonal Antibody Failure in Immunocompromised COVID-19 Patients: A Systematic Review and Meta-Analysis of Individual Patient Data.
Reviews in medical virology·
- DOI
- 10.1002/rmv.70185
- PMID
- 42536824
- PMCID
- —
- OpenAlex
- —
- Study type
- Systematic review
- Publisher
- Publisher unavailable
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The findings concern a treatment option for immunocompromised patients with persistent infection after monoclonal antibody failure, but the supplied abstract does not establish comparative effectiveness or causality.
Structured evidence summary
Research question
The study examined whether COVID-19 convalescent plasma promoted SARS-CoV-2 clearance in immunocompromised patients with persistent viraemia after anti-Spike monoclonal antibody therapy, and whether biological factors were associated with clearance.
Study design
Systematic review with individual participant data meta-analysis. It included eligible published cases and unpublished investigator-submitted cases, and used logistic regression to assess factors associated with clearance.
Population and setting
The population comprised 47 immunocompromised patients with persistent SARS-CoV-2 positivity after anti-Spike monoclonal antibody therapy: 30 cases from 12 published studies and 17 unpublished cases.
Main findings
SARS-CoV-2 clearance following convalescent plasma transfusion was reported in 33 of 47 patients (70.2%), with a mean of 2.7 plasma units administered. Total transfused volume was positively associated with clearance in logistic regression.
Public-health relevance
The findings concern a treatment option for immunocompromised patients with persistent infection after monoclonal antibody failure, but the supplied abstract does not establish comparative effectiveness or causality.
Important limitations
The evidence is based on 47 cases, including unpublished cases, and the abstract does not describe a control group or sufficient detail to assess bias, heterogeneity, or causal effects. This summary is limited to the supplied single-article abstract and metadata and requires the original paper for decision-grade interpretation.
GIDS interpretation
The article is relevant to GIDS discovery and contextual review because it concerns COVID-19 treatment, vaccination-related convalescent plasma, immunocompromised patients, and persistent SARS-CoV-2 infection. The supplied evidence does not connect these findings to any live surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.